2023年6月6日

新聞分享這篇文章提供的精密泰薇是第一個FDA批準醫療團隊的預測建模工具,規劃TAVR程序一個手術,我們的技術有助於避免並發症,重複的幹預措施,幫助終生規劃最優結構性心髒保健,有可能節省數十億美元。”——拉克希便博士,FACC FAIMBE,創始人兼首席技術官都柏林,俄亥俄州,美國,6月6日2023 / EINPresswire.com——便模擬今天宣布它已收到FDA批準的第一個產品——精密泰薇。便旨在將先進的人工智能(AI)簡況個性化的計算機預測建模對於改善病人狀況,增強終身計劃和減少結構性心髒病相關的治療費用。“便模擬賦予每個核心團隊與關鍵的見解保證患者個體的識別最好的照顧,定製獨特的環境和解剖學,Lakshmi (Prasad)便說,博士,FACC FAIMBE,創始人兼首席技術官。“一次一個手術,我們的技術有助於避免並發症,重複的幹預措施,幫助終生規劃最優結構心髒保健,並且有可能節省數十億美元的不必要的成本可預防並發症。“需要pre-procedure TAVR建模…超過五百萬美國人被診斷為心髒瓣膜疾病每年。最終,許多的患者將接受手術以取代損壞的閥門。事實上,多種幹預措施可能需要一生,所以這是非常重要的。經導管主動脈瓣置換術(TAVR),微創手術,成為關心的標準取代患病的主動脈瓣。在TAVR,醫生訪問和一個小切口心髒的腿或腹股溝,然後喂導管通過血管,使用先進的成像新更換閥心的地方。在2021年,有超過91000 TAVR程序。 TAVR reduces the need for, and the risks of, open-heart surgery. Revolutionizing structural heart care...“Our goal is to enter into the market and demonstrate our value to physicians, providers and TAVR centers,” says Founder and CEO Teri Sirset. “Receiving FDA clearance is a testament to our unwavering commitment to revolutionize healthcare through AI technology and personalized computer simulations. Our game-changing approach has paved the way for the first approved personalized computer simulations in the heart valve space. While the journey to approval typically spans years, we shattered expectations by achieving this milestone in less than 14 months. As a company founded in December 2019, before the onset of the global pandemic, we navigated through unprecedented challenges and built a robust infrastructure during the tumultuous times of COVID-19. This achievement showcases our resilience and dedication to transforming patient care, one groundbreaking innovation at a time.” The foundational technology for Precision TAVI was initially licensed through The Ohio State University (OSU), and subsequently through an inter-institutional agreement between OSU, Georgia Institute of Technology, Emory University, and Piedmont Hospital Atlanta. "Georgia Tech is proud to have played a role in creating advanced AI-based technology that can revolutionize the decision-making process for efficient and optimal treatment planning, thereby improving patient outcomes." says Georgia Tech’s Vice President of Commercialization Dr. Raghupathy Sivakumar. About DASI Simulations - Founded in 2019, DASI Simulations, based in Dublin, Ohio, performs advanced individualized computational predictive modeling for heart surgery candidates. The modeling is powered by artificial intelligence and computer vision to help heart surgeons better plan for the surgery and any potential complications, which leads to improved patient outcomes and reduced costs associated with structural heart disease surgeries. For more information, visit www.dasisim.com or email news@dasisim.com. The DASI platform is built upon an extensive body of interdisciplinary research conducted in the colleges of Engineering and Medicine at The Ohio State University and Georgia Institute of Technology. The technology was licensed from the Ohio State Innovation Foundation in 2020 and 2022. Kelly Arledge